Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rodon

Showing results (51-60 of 247) with videos related to

Pageof 25
Sort By:
Clinical Neurology and Neurosurgery|October 23, 2015
Prognostic implications of epilepsy in glioblastomasManuel Toledo, Silvana Sarria-Estrada, Manuel Quintana, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
The Oncologist|June 5, 2024
Metastatic extraneural glioblastoma diagnosed with molecular testingNazanin K Majd, Henry Hiep Vo, Cesar A Moran, et al.
The Oncologist|March 30, 2018
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid TumorsGerald Edelman, Jordi Rodon, Joanne Lager, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2018
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric CancerFunda Meric-Bernstam, Amber M Johnson, Ecaterina E Ileana Dumbrava, et al.
NPJ Precision Oncology|December 2, 2021
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibitionNiamh Coleman, Vivek Subbiah, Shubham Pant, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathiesRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2017
First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumoursJordi Rodon, Sophie Postel-Vinay, Antoine Hollebecque, et al.
Pageof 25

Showing results (51-60 of 247) with videos related to

Sort By:
Pageof 25
Clinical Neurology and Neurosurgery|October 23, 2015
Prognostic implications of epilepsy in glioblastomasManuel Toledo, Silvana Sarria-Estrada, Manuel Quintana, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
The Oncologist|June 5, 2024
Metastatic extraneural glioblastoma diagnosed with molecular testingNazanin K Majd, Henry Hiep Vo, Cesar A Moran, et al.
The Oncologist|March 30, 2018
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid TumorsGerald Edelman, Jordi Rodon, Joanne Lager, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2018
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric CancerFunda Meric-Bernstam, Amber M Johnson, Ecaterina E Ileana Dumbrava, et al.
NPJ Precision Oncology|December 2, 2021
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibitionNiamh Coleman, Vivek Subbiah, Shubham Pant, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathiesRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2017
First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumoursJordi Rodon, Sophie Postel-Vinay, Antoine Hollebecque, et al.
Pageof 25